Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.
cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions.
Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.
R1 Therapeutics is a clinical-stage biopharmaceutical company that develops first-in-class treatments for kidney disease patients.
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.
Addition Therapeutics develops RNA-only therapeutics using PRINT technology for genetic medicine.
Vera Therapeutics is a biotechnology company developing innovative biologic therapeutics with transformative clinical potential.
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.
Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.
Glycomine is an early-stage biotech working on replacement therapies for rare diseases.
Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
Timberlyne Therapeutics is a biopharmaceutical company that develops therapies for autoimmune diseases.
Personalis is a contract research organization and genome-scale diagnostics services company specializing in genome guided medicine.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases.
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
Ascend Gene & Cell Therapies is a model for gene and cell therapy manufacturing.
Venatorx Pharmaceuticals develops anti-infectives to treat multi-drug-resistant bacterial infections and viral infections.
Abingworth has invested in 49 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Abingworth's top investment sectors include Biotechnology, Health Care, Therapeutics, Biopharma, Pharmaceutical. The firm invests across 16 different industry categories.
Among tracked funding rounds, CRISPR Therapeutics received $550.0M in a Post-IPO Debt round. Abingworth's total known invested capital is $5.2B.
Abingworth's average investment size is $105.8M across its portfolio of 49 companies.
Recent Abingworth portfolio additions include Jasper Therapeutics, Q32 Bio, Entact Bio, cAMPfield Therapeutics, Spruce Biosciences. These companies were founded in 2020 or later.